Combined antihypertensive and lipid-lowering therapy in experimental glomerulonephritis

Rhonda Rubin, Sharon Silbiger, Leonarda Sablay, Joel Neugarten

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

We examined the interrelation between systemic hypertension, hyperlipidemia, and progressive renal injury in experimental glomerulonephritis. Induction of nephrotoxic serum nephritis in Sprague- Dawley rats led to systemic hypertension and hyperlipidemia. Four groups of rats were studied over a 16-week period: (1) untreated nephritic rats; (2) nephritic rats treated with hydralazine, reserpine, and lasix (AH); (3) nephritic rats treated with lovastatin (4 mg/kg) (Lova); and (4) nephritic rats treated with combined antihypertensive/lipid-lowering therapy (AH/Lova). Systolic blood pressure rose progressively in untreated rats (152±4 mm Hg at 16 weeks). Blood pressure was reduced by antihypertensive therapy (P<.001) (108±2 mm Hg in the AH group and [11±3 mm Hg in the AH/Lova group) but remained elevated in animals treated with lovastatin alone (P>.05) (156±3 mm Hg in the Lova group). Serum cholesterol rose progressively in untreated rats (3.70±0.85 mmol/L [143±33 mg/dL] at 16 weeks). The rise in serum cholesterol was prevented by lovastatin therapy (P<.001) (2.22±0.41 mmol/L [86±16 mg/dL] in the Lova group and 2.09±0.52 mmol/L [81±2 mg/dL] in the AH/Lova group) but not antihypertensive therapy (P>.05) (2.92±0.65 mmol/L [1113±25 mg/dL] in the AH group). Proteinuria was reduced by antihypertensive therapy (P<.001) and lipid-lowering therapy (P<.05) (16- week values: 1.069±0.167 g/d in untreated rats, 0.663±0.164 g/d in the Lova group, 0.392±0.051 g/d in the AH group, and 0.176±0.035 g/d in the AH/Lova group). Glomerular injury score was significantly reduced by antihypertensive therapy (P<.01) and lipid-lowering therapy (P<.05). Glomerular injury score was lowest in animals receiving combined therapy, reflecting an interaction between these therapies (P<.01) (untreated, 173±29; Lova, 128±24; AH, 111±22; AH/Lova, 48±11). Our results suggest that both hypertension and hyperlipidemia accelerate glomerular sclerosis in experimental glomerulonephritis and that combined therapy of these disorders may best limit progressive renal injury.

Original languageEnglish (US)
Pages (from-to)92-95
Number of pages4
JournalHypertension
Volume23
Issue number1
StatePublished - Jan 1994

Fingerprint

Investigational Therapies
Glomerulonephritis
Antihypertensive Agents
Lipids
Kidney
Hyperlipidemias
Therapeutics
Lovastatin
Wounds and Injuries
Blood Pressure
Hypertension
Serum
Cholesterol
Hydralazine
Nephritis
Reserpine
Furosemide
Sclerosis
Proteinuria
Sprague Dawley Rats

Keywords

  • glomerulonephritis
  • hyperlipidemia
  • hypertension

ASJC Scopus subject areas

  • Internal Medicine

Cite this

Combined antihypertensive and lipid-lowering therapy in experimental glomerulonephritis. / Rubin, Rhonda; Silbiger, Sharon; Sablay, Leonarda; Neugarten, Joel.

In: Hypertension, Vol. 23, No. 1, 01.1994, p. 92-95.

Research output: Contribution to journalArticle

Rubin, Rhonda ; Silbiger, Sharon ; Sablay, Leonarda ; Neugarten, Joel. / Combined antihypertensive and lipid-lowering therapy in experimental glomerulonephritis. In: Hypertension. 1994 ; Vol. 23, No. 1. pp. 92-95.
@article{266b946e96fd4543ac506b1cf8d2f117,
title = "Combined antihypertensive and lipid-lowering therapy in experimental glomerulonephritis",
abstract = "We examined the interrelation between systemic hypertension, hyperlipidemia, and progressive renal injury in experimental glomerulonephritis. Induction of nephrotoxic serum nephritis in Sprague- Dawley rats led to systemic hypertension and hyperlipidemia. Four groups of rats were studied over a 16-week period: (1) untreated nephritic rats; (2) nephritic rats treated with hydralazine, reserpine, and lasix (AH); (3) nephritic rats treated with lovastatin (4 mg/kg) (Lova); and (4) nephritic rats treated with combined antihypertensive/lipid-lowering therapy (AH/Lova). Systolic blood pressure rose progressively in untreated rats (152±4 mm Hg at 16 weeks). Blood pressure was reduced by antihypertensive therapy (P<.001) (108±2 mm Hg in the AH group and [11±3 mm Hg in the AH/Lova group) but remained elevated in animals treated with lovastatin alone (P>.05) (156±3 mm Hg in the Lova group). Serum cholesterol rose progressively in untreated rats (3.70±0.85 mmol/L [143±33 mg/dL] at 16 weeks). The rise in serum cholesterol was prevented by lovastatin therapy (P<.001) (2.22±0.41 mmol/L [86±16 mg/dL] in the Lova group and 2.09±0.52 mmol/L [81±2 mg/dL] in the AH/Lova group) but not antihypertensive therapy (P>.05) (2.92±0.65 mmol/L [1113±25 mg/dL] in the AH group). Proteinuria was reduced by antihypertensive therapy (P<.001) and lipid-lowering therapy (P<.05) (16- week values: 1.069±0.167 g/d in untreated rats, 0.663±0.164 g/d in the Lova group, 0.392±0.051 g/d in the AH group, and 0.176±0.035 g/d in the AH/Lova group). Glomerular injury score was significantly reduced by antihypertensive therapy (P<.01) and lipid-lowering therapy (P<.05). Glomerular injury score was lowest in animals receiving combined therapy, reflecting an interaction between these therapies (P<.01) (untreated, 173±29; Lova, 128±24; AH, 111±22; AH/Lova, 48±11). Our results suggest that both hypertension and hyperlipidemia accelerate glomerular sclerosis in experimental glomerulonephritis and that combined therapy of these disorders may best limit progressive renal injury.",
keywords = "glomerulonephritis, hyperlipidemia, hypertension",
author = "Rhonda Rubin and Sharon Silbiger and Leonarda Sablay and Joel Neugarten",
year = "1994",
month = "1",
language = "English (US)",
volume = "23",
pages = "92--95",
journal = "Hypertension",
issn = "0194-911X",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - Combined antihypertensive and lipid-lowering therapy in experimental glomerulonephritis

AU - Rubin, Rhonda

AU - Silbiger, Sharon

AU - Sablay, Leonarda

AU - Neugarten, Joel

PY - 1994/1

Y1 - 1994/1

N2 - We examined the interrelation between systemic hypertension, hyperlipidemia, and progressive renal injury in experimental glomerulonephritis. Induction of nephrotoxic serum nephritis in Sprague- Dawley rats led to systemic hypertension and hyperlipidemia. Four groups of rats were studied over a 16-week period: (1) untreated nephritic rats; (2) nephritic rats treated with hydralazine, reserpine, and lasix (AH); (3) nephritic rats treated with lovastatin (4 mg/kg) (Lova); and (4) nephritic rats treated with combined antihypertensive/lipid-lowering therapy (AH/Lova). Systolic blood pressure rose progressively in untreated rats (152±4 mm Hg at 16 weeks). Blood pressure was reduced by antihypertensive therapy (P<.001) (108±2 mm Hg in the AH group and [11±3 mm Hg in the AH/Lova group) but remained elevated in animals treated with lovastatin alone (P>.05) (156±3 mm Hg in the Lova group). Serum cholesterol rose progressively in untreated rats (3.70±0.85 mmol/L [143±33 mg/dL] at 16 weeks). The rise in serum cholesterol was prevented by lovastatin therapy (P<.001) (2.22±0.41 mmol/L [86±16 mg/dL] in the Lova group and 2.09±0.52 mmol/L [81±2 mg/dL] in the AH/Lova group) but not antihypertensive therapy (P>.05) (2.92±0.65 mmol/L [1113±25 mg/dL] in the AH group). Proteinuria was reduced by antihypertensive therapy (P<.001) and lipid-lowering therapy (P<.05) (16- week values: 1.069±0.167 g/d in untreated rats, 0.663±0.164 g/d in the Lova group, 0.392±0.051 g/d in the AH group, and 0.176±0.035 g/d in the AH/Lova group). Glomerular injury score was significantly reduced by antihypertensive therapy (P<.01) and lipid-lowering therapy (P<.05). Glomerular injury score was lowest in animals receiving combined therapy, reflecting an interaction between these therapies (P<.01) (untreated, 173±29; Lova, 128±24; AH, 111±22; AH/Lova, 48±11). Our results suggest that both hypertension and hyperlipidemia accelerate glomerular sclerosis in experimental glomerulonephritis and that combined therapy of these disorders may best limit progressive renal injury.

AB - We examined the interrelation between systemic hypertension, hyperlipidemia, and progressive renal injury in experimental glomerulonephritis. Induction of nephrotoxic serum nephritis in Sprague- Dawley rats led to systemic hypertension and hyperlipidemia. Four groups of rats were studied over a 16-week period: (1) untreated nephritic rats; (2) nephritic rats treated with hydralazine, reserpine, and lasix (AH); (3) nephritic rats treated with lovastatin (4 mg/kg) (Lova); and (4) nephritic rats treated with combined antihypertensive/lipid-lowering therapy (AH/Lova). Systolic blood pressure rose progressively in untreated rats (152±4 mm Hg at 16 weeks). Blood pressure was reduced by antihypertensive therapy (P<.001) (108±2 mm Hg in the AH group and [11±3 mm Hg in the AH/Lova group) but remained elevated in animals treated with lovastatin alone (P>.05) (156±3 mm Hg in the Lova group). Serum cholesterol rose progressively in untreated rats (3.70±0.85 mmol/L [143±33 mg/dL] at 16 weeks). The rise in serum cholesterol was prevented by lovastatin therapy (P<.001) (2.22±0.41 mmol/L [86±16 mg/dL] in the Lova group and 2.09±0.52 mmol/L [81±2 mg/dL] in the AH/Lova group) but not antihypertensive therapy (P>.05) (2.92±0.65 mmol/L [1113±25 mg/dL] in the AH group). Proteinuria was reduced by antihypertensive therapy (P<.001) and lipid-lowering therapy (P<.05) (16- week values: 1.069±0.167 g/d in untreated rats, 0.663±0.164 g/d in the Lova group, 0.392±0.051 g/d in the AH group, and 0.176±0.035 g/d in the AH/Lova group). Glomerular injury score was significantly reduced by antihypertensive therapy (P<.01) and lipid-lowering therapy (P<.05). Glomerular injury score was lowest in animals receiving combined therapy, reflecting an interaction between these therapies (P<.01) (untreated, 173±29; Lova, 128±24; AH, 111±22; AH/Lova, 48±11). Our results suggest that both hypertension and hyperlipidemia accelerate glomerular sclerosis in experimental glomerulonephritis and that combined therapy of these disorders may best limit progressive renal injury.

KW - glomerulonephritis

KW - hyperlipidemia

KW - hypertension

UR - http://www.scopus.com/inward/record.url?scp=0028137806&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028137806&partnerID=8YFLogxK

M3 - Article

C2 - 8282335

AN - SCOPUS:0028137806

VL - 23

SP - 92

EP - 95

JO - Hypertension

JF - Hypertension

SN - 0194-911X

IS - 1

ER -